Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)

Truist Financial analyst Robyn Karnauskas maintained a Buy rating on Tourmaline Bio (TRML – Research Report) today. The company’s shares closed last Friday at $24.67.

According to TipRanks, Karnauskas is a 4-star analyst with an average return of 6.8% and a 48.73% success rate. Karnauskas covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Tourmaline Bio, and Bristol-Myers Squibb.

Currently, the analyst consensus on Tourmaline Bio is a Strong Buy with an average price target of $56.80, a 130.24% upside from current levels. In a report released on March 21, Guggenheim also reiterated a Buy rating on the stock with a $50.00 price target.

Based on Tourmaline Bio’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $2.13 million. In comparison, last year the company had a net profit of $35.67 million

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TRML in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tourmaline Bio (TRML) Company Description:

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.